Cover Image
市場調查報告書

循環腫瘤細胞 (CTC)的診斷:技術和全球市場

Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets

出版商 BCC Research 商品編碼 294447
出版日期 內容資訊 英文 302 Pages
訂單完成後即時交付
價格
Back to Top
循環腫瘤細胞 (CTC)的診斷:技術和全球市場 Circulating Tumor Cell (CTC) Diagnostics: Technologies and Global Markets
出版日期: 2018年04月12日 內容資訊: 英文 302 Pages
簡介

循環腫瘤細胞 (CTC) 技術的全球市場預計從2017年的約46億美元,到2022年擴大到約103億美元,預計在預測期間以17.6%的年複合成長率成長。

本報告提供全球循環腫瘤細胞 (CTC) 診斷市場相關分析,主要的技術及商業性方面的研究,出示市場規模,產業的成長率及市場趨勢彙整,CTC市場上最近的趨勢,主要的企業的簡介彙整。

第1章 簡介

第2章 摘要、亮點

第3章 循環腫瘤細胞 (CTC)

  • 癌症
  • 循環腫瘤細胞
  • 癌症幹細胞 (CSC)
    • 循環腫瘤細胞:潛在性用途
    • 增生活動
    • 循環腫瘤細胞上的上皮標記遺傳基因
    • 循環腫瘤細胞和幹細胞樣表型
    • CTC及主癌細胞:比較
    • 轉移
    • 未來的方向性
  • 癌症患者的轉移的進行
    • 循環腫瘤細胞的移動
    • 遠隔轉移的重要標記
    • 循環腫瘤細胞的檢測
  • 手法
    • 細胞搜尋方法
    • 檢測的課題
    • 循環腫瘤DNA臨床用途
    • 治療應答的預知因素的循環腫瘤細胞
    • CTC的檢測標準:用途
    • 結論

第4章 癌症的發病率

  • 癌症發病率的全世界的增加
    • 癌症的原因
    • 癌症的風險要素
    • 癌症的負擔
    • 早期發現
    • 治療
    • 痛苦緩和治療
    • WHO的反應
    • 全球性癌症的統計
  • 癌症全世界的影響
    • 全球模式
    • 癌症的未來
    • 美國的癌症的發病率
    • 全球乳癌
    • 大腸癌
    • 前列腺癌
    • 歐洲的癌症
    • 亞洲的前列腺癌
    • 其他各國
    • 結論

第5章 技術

  • 循環腫瘤細胞的發現
    • 為何是CTC?
    • 目前CTC檢測、分離手法
    • 新的檢測技術
    • 癌症的預後
    • CTC檢測技術:必要條件
    • 使用了核酸的手法
    • 臨床試驗
    • 摘要
    • 新興技術

第6章 循環腫瘤細胞與癌症診斷

  • 診斷的CTC的利用
    • 目前手法、應用
    • 前列腺癌的循環腫瘤細胞:實例分析
    • 比較診斷的CTC
    • 處於開發階段的更新的技術
    • CTC的分子分析
    • 結論

第7章 臨床試驗的CTC

  • CTC診斷

第8章 循環腫瘤細胞市場

  • 侵入性癌症
    • 癌症存活率
    • 全球年度腫瘤市場
    • 癌症治療
    • 老齡化和癌症
    • 癌症治療藥的開發平台
    • 日本的癌症治療藥市場
    • 乳癌
    • 大腸癌
    • 前列腺癌
    • 化療市場
    • 癌症檢驗市場
    • 目前癌症診斷檢驗
    • 普遍的腫瘤檢驗:可能嗎?
    • 癌症生物標記檢驗市場
    • 分子診斷
    • 癌症生物標記檢驗
    • 癌症疾病管理
    • 客製化的癌症檢驗
    • CTC市場:新方法
    • 臨床診斷市場
    • 市場現狀
    • 未來及下個階段

第9章 專利概要

  • 主要專利

第10章 主要企業的簡介

關於BCC Research

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHM153B

Report Highlights

The global market for circulating tumor cell technology will grow from nearly $4.6 billion in 2017 to around $10.3 billion by 2022 with a compound annual growth rate (CAGR) of 17.6% for the period of 2017-2022.

Report Includes:

  • 118 Tables
  • An overview of the global market for cancer diagnostics, based on circulating tumor cells, which are used to increase understanding of tumor cell biology and metastatic cancer as a disease.
  • Analyses of global market trends, with data from 2016, estimates from 2017, and projections of compound annual growth rates (CAGRs) through 2022.
  • Discussions covering the advantages and disadvantages of CTC enrichment techniques.
  • Estimations of cancer incidence, cancer deaths, new cases by type in the United States, and breast cancer statistics and facts.
  • Examination of growth opportunities and drivers in the CTC market and recent breakthroughs in research, along with a patent analysis.
  • Information about the clinical testing, prognostic, and monitoring markets for CTCs in cancer.
  • Coverage of approved CTC tests and their markets, and the regulatory environment.
  • Company profiles of major players across various product categories, including Cytotrack, Menarini-Silicon Biosystems And A. Menarini Diagnostics (Veridex Llc), Greiner Bio-One Gmbh, Cynvenio Biosystems Inc., Biofluidica Microtechnologies Llc and Advanced Cell Diagnostics

Report Scope

The scope of this study is clinical testing, prognostic and monitoring markets for CTCs in cancer. The report also includes the clinical research segment, currently approved CTC tests and their markets. The regulatory environment, current technologies, new technologies, cancer incidence, market projections and market share along with the latest trends and new developments in this area are included to support the clinical testing market.

The research segment of the market includes numerous competitors with different capabilities, developing and commercializing products such as CTC isolation devices and protocols, CTC characterization reagents, assay and instrumentation, and various identification technologies based on cell imaging. These market players include specialized or research-based companies that contribute considerably to the technological advancements in the field of CTC technologies.

The data collected for the report is focused on breast, prostate and colorectal cancers for which clinical data and tests are available currently on the market. CTCs in other cancers are being researched and some are in clinical trials; these are not included within the scope of this report.

Analyst Credentials

Usha Nagavarapu, PhD, is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification including investigational new drug (IND)-enabling studies and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. Usha has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.

Table of Contents

Chapter 1: Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Intended Audience
  • Scope of the Study
  • Methodology
  • Information Sources
  • Geographic Breakdown
  • Analyst's Credentials
  • Related BCC Research Reports

Chapter 2: Summary and Highlights

Chapter 3: Circulating Tumor Cells

  • Cancer
    • Recent Advances in Technology
    • Invasive Power
  • Circulating Tumor Cells
    • Phenotypic Characteristics
    • CTC Clusters
    • CTC Detection
  • Cancer Stem Cells (CSCs)
    • Circulating Tumor Cells - Potential Uses
    • Proliferative Activity
    • Epithelial Marker Genes on Circulating Tumor Cells
    • Circulating Tumor Cells and Stem Cell-Like Phenotype
    • CTCs and Primary Tumor Cells: Comparison
    • Metastasis
    • Future Directions
  • Metastatic Development in Cancer Patients
    • Circulating Tumor Cell Migration
    • Important Markers of Distant Metastasis
    • Circulating Tumor Cell Detection
  • Methods
    • CellSearch Method
    • Epic Sciences Method
    • Maintrac
    • ISET Test
    • Challenges for Detection
    • Clinical Application of Circulating Tumor DNA
    • Circulating Tumor Cells as Predictor of Response to Therapy
    • Measurement of CTCs - Applications
    • Conclusion

Chapter 4: Incidence of Cancer

  • Worldwide Growth in the Incidence of Cancer
    • Causes of Cancer
    • Risk Factors for Cancers
    • Burden of Cancer
    • Avoiding Risk Factors
    • Early Detection
    • Treatment
    • Palliative Care
    • World Health Organization Response
    • World Cancer Statistics
  • Cancer and the Global Impact
    • Global Patterns
    • Future of Cancer
    • Common Types of Cancers
    • U.S. Cancer Incidence
    • Global Breast Cancer
    • Colorectal Cancer
    • Prostate Cancer
    • Cancer in Europe
    • Prostate Cancer in Asia
    • Other Nations
    • Conclusions

Chapter 5: Technologies

  • Finding Circulating Tumor Cells
    • Why CTCs?
    • Current CTC Detection and Isolation Methods
    • New Technologies for Detection
    • Cancer Prognosis
    • CTC Detection Techniques - Requirements
    • Nucleic Acid-based Methods
    • Clinical Testing
    • Summary
    • New Emerging Technologies

Chapter 6: Circulating Tumor Cells and Cancer Diagnostics

  • Use of CTCs for Diagnosis
    • Current Methods and Applications
    • Circulating Tumor Cells in Prostate Cancer: Case Studies
    • CTCs in Companion Diagnostics
    • Newer Technologies in Development
    • Molecular Analyses of CTC
    • Conclusions

Chapter 7: CTCs in Clinical Trials

  • CTC Diagnostics
    • Circulating Tumor Cell Technology
    • Potential Therapeutic Uses of Circulating Tumor Cells
    • Challenges in the Detection of Circulating Tumor Cells
    • CTCs as Clinical Biomarkers
    • PCR-based Markers
    • Circulating Tumor Cells in Cancer - Current Status
    • Prognostic and Predictive Value of CTCs
    • CTCs in Clinical Cancer Management
    • Existing Technologies in Clinical Trials
    • Clinical Studies Using CellSearch Technology
    • Approvals
    • Recent Studies
    • Possible Use of CTCs and DTCs as New Biomarkers
    • Clinical Applications
    • Application of CTC Technologies to Clinical Testing
    • CTC Technologies for Clinical Development
    • Standard Recommendations
    • CTC Number as a Prognostic Biomarker
    • Prognostic Studies
    • CTCs as a Surrogate Response Biomarker
    • CTCs as a Real-time Biopsy
    • CTC Chip Technology and EGFR Mutation Analysis
    • CTC Characterization after Enrichment Using the CellSearch Platform
    • Final Remarks

Chapter 8: Circulating Tumor Cell Market

  • Invasive Cancer
    • Cancer Survival
    • Global Annual Oncology Market
    • Cancer Therapy
    • Aging and Cancer
    • Cancer Drug Pipeline
    • Cancer Costs in the U.S
    • Japan Oncology Drugs Market
    • Breast Cancer
    • Colon and Rectum
    • Prostate
    • Chemotherapy Market
    • Cancer Testing Market
    • Current Cancer Diagnostic Tests
    • A Universal Tumor Test - Is it Possible?
    • Cancer Biomarker Testing Market
    • Molecular Diagnostics
    • Cancer Biomarker Tests
    • Cancer Disease Management
    • Personalized Cancer Testing
    • Circulating Tumor Cell Market - A New Approach
    • Clinical Diagnostics Market
    • Current Status of the Market
    • Future and Next Steps

Chapter 9: Patents Overview

  • Key Patents
    • Menarini-Silicon Biosystems/Veridex
    • Magsweeper
    • Scripps Research Institute (EPIC Sciences)
    • CellPoint Diagnostics
    • University of Washington
    • Biofluidica
    • Adnagen
    • Filtini
    • Ikonisys
    • Aviva Biosciences
    • Harvard University - Mehmet Toner, PhD
    • Cellective Dx
    • Johns Hopkins University
    • Medical Discovery Partners
    • Cynvenio Biosystems
    • ScreenCell
    • Canopus Bioscience
    • Advanced Cell Diagnostics
    • Biocept
    • Truecells
    • Roche Molecular Systems and the University of North Carolina
    • Cellectar Biosciences
    • The General Hospital Corp.
    • The Trustees of the University of Pennsylvania Patents
    • Epic Sciences
    • Immunomedics

Chapter 10: Selected Company Profiles

  • Companies
  • Key Players
    • Key Company Profiles

About BCC Research

  • About BCC Research
  • BCC Membership
  • BCC Custom Research

List of Tables

  • Summary Table: Global Circulating Tumor Cell Technology Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 1: Categories of Stem Cells
    • Table 2: Product Categories
    • Table 3: Key Success Factors of CTCs
    • Table 4: Types of CTCs
    • Table 5: Circulating Tumor Cells - Features
    • Table 6: Metastatic Cascade
    • Table 7: EPCAM-based Assays
    • Table 8: CellSearch Tests
    • Table 9: Liquid Biopsy Technologies
    • Table 10: Cancer - Key Facts
    • Table 11: Cancer Causes
    • Table 12: Cancer Causing Factors
    • Table 13: Cancer Screening Methods
    • Table 14: Noncommunicable Diseases Action Plan
    • Table 15: Global Cancer Incidence and Mortality, 2012 and 2035 (Millions)
    • Table 16: Cancer in 2013
    • Table 17: Global Cancer Statistics for the Most Common Cancers, 2012
    • Table 18: Increase in Cancer Burden - Factors
    • Table 19: Main Types of Cancers and Associated Mortality
    • Table 20: General Global Cancer Incidence, by Type
    • Table 21: Common Types of Cancers in U.S., Estimated New Cases, 2013
    • Table 22: Global Breast Cancer Incidence, 2012-2022
    • Table 23: Global Breast Cancer Facts
    • Table 24: Breast Cancer in the U.S.
    • Table 25: Breast Cancer in U.S., 2012-2022
    • Table 26: Global Colorectal Cancer, 2012-2022
    • Table 27: Global Colorectal Cancer Incidence (Estimated): Mortality and Prevalence, 2012 (Thousands)
    • Table 28: Colorectal Cancer Incidence Estimates in U.S., 2012-2022
    • Table 29: Number of People Living with Colorectal Cancer Estimates in U.S., 2016
    • Table 30: Colon and Rectal Cancer Incidence Estimates in U.S., 2013-2022
    • Table 31: Incidence and Deaths for Prostate Cancer, 2013 (Thousands)
    • Table 32: Prostate Cancer Incidence and Mortality Worldwide, 2012 (Thousands)
    • Table 33: Highest Incidence of Prostate Cancer, by Country, 2012
    • Table 34: Global Estimated Prostate Cancer Deaths: Age-Standardized Mortality Rates per 100,000 Men, 2012
    • Table 35: Global Estimated New Cases of Prostate Cancer, 2012-2022
    • Table 36: Prostate Cancer Statistics, 2016
    • Table 37: Estimated New Cases and Deaths of Prostate Cancer in U.S., 2012-2016 (Number)
    • Table 38: Estimated Prostate Cancer Cases in U.S., 2020 and 2030 (Number)
    • Table 39: Prostate Cancer Statistics: New Cases and Deaths in U.S., by Race, 2007-2012
    • Table 40: Prostate Cancer Stage and Survival Rate (%)
    • Table 41: Incidence Rates by Race in U.S., 2005-2009
    • Table 42: Mortality Rates by Race in U.S., 2005-2009
    • Table 43: Relative Survival Rate for Prostate Cancer Patients (%)
    • Table 44: Five-year Relative Survival by Stage at the Time of Diagnosis
    • Table 45: Estimated Prostate Cancer in Canada, 2015
    • Table 46: Estimated Prostate Cancer Mortality in EU27 Countries: Age-Standardized Mortality Rates per 100,000 Men, 2012
    • Table 47: Prostate Cancer Deaths in U.K.: Rate per 100,000 People, 2014
    • Table 48: Estimated Prostate Cancer Diagnosed in 2016
    • Table 49: Potential Applications of CTC-based Diagnostics
    • Table 50: Clinical Relevance of CTC
    • Table 51: CTC Enrichment Methods
    • Table 52: Techniques Used for CTC Enrichment
    • Table 53: Techniques Used for CTC Analysis
    • Table 54: Enumeration Techniques
    • Table 55: Functional Assays
    • Table 56: Circulating Tumor Cells Technologies
    • Table 57: Micro-Count Features: A New Technology
    • Table 58: CTC Assay Pre-Analytical Validation Considerations
    • Table 59: CTC Assay Analytical Validation Considerations
    • Table 60: CTC Assay Post-Analytical Validation Considerations
    • Table 61: Current Enrichment Assays for CTCs
    • Table 62: CTC Enumeration Assays
    • Table 63: Characterization Assays for CTCs
    • Table 64: Key Features of IVD CTC Tests
    • Table 65: Prostate Cancer Diagnosis and Role of CTCs
    • Table 66: Current Diagnostic Methods
    • Table 67: ApoStream Key Features
    • Table 68: Canopus Bioscience Technology - Benefits
    • Table 69: CellOptics' Cancer Application
    • Table 70: CellOptics' Key Features - Enrichment
    • Table 71: CellOptics' Key Features - Labeling
    • Table 72: CellOptics' Key Features - Detection
    • Table 73: ISET Test - Specifications
    • Table 74: CTC Technologies for Clinical Management
    • Table 75: CTC Technologies for Clinical Management
    • Table 76: CTC Assay Clinical Readiness Evaluation
    • Table 77: CTC Assay Analytical Validation Considerations
    • Table 78: CTC Qualification Studies
    • Table 79: Global Cancer Incidence - Estimates, 2008-2030 (Millions)
    • Table 80: Global Cancer Survivors, 2008 (Millions)
    • Table 81: Burden of Cancer in U.S., 2016
    • Table 82: U.S. Cancer Survivors, 2008-2022 (Millions)
    • Table 83: Male Cancer Survivors (%)
    • Table 84: Female Cancer Survivors (%)
    • Table 85: Global Cancer Drug Companies
    • Table 86: Global Cancer Drug Market, Through 2022 ($ Millions)
    • Table 87: Drugs Approved in 2017
    • Table 88: Cancer Forecast in U.S., 2020 - Key Facts
    • Table 89: Cancer Care Cost in U.S., 2010 and 2020 ($ Billions)
    • Table 90: Global In Vitro Diagnostics Market, Through 2022 ($ Millions)
    • Table 91: Key Players
    • Table 92: Significant Developments in Cancer Follow-Up
    • Table 93: Cancer Tests and Limitations - the Case Against Development of a Universal Test
    • Table 94: Global Cancer Biomarkers Market, Through 2022 ($ Millions)
    • Table 95: Key Players
    • Table 96: Global Molecular Diagnostics Market, Through 2022 ($ Millions)
    • Table 97: CTCs - Differentiating Features
    • Table 98: Stem Cell Market Overview
    • Table 99: Key Companies Selling Stem Cell Research Products
    • Table 100: CTC Companies with Promising Products
    • Table 101: Clinical Use of CellSearch System
    • Table 102: Estimated Pricing (Dollars)
    • Table 103: CellSearch Kit
    • Table 104: Global Circulating Tumor Cell Testing Market, by Region, Through 2022 ($ Millions)
    • Table 105: Global Circulating Tumor Cells for Prostate Cancer Market, by Region, Through 2022 ($ Millions)
    • Table 106: Global Circulating Tumor Cells for Breast Cancer Market, by Region, Through 2022 ($ Millions)
    • Table 107: Global Circulating Tumor Cells for Colorectal Cancer Market, by Region, Through 2022 ($ Millions)
    • Table 108: U.S. Circulating Tumor Cells for Prostate Cancer Market, Through 2022 ($ Millions)
    • Table 109: U.S. Circulating Tumor Cells Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 110: European Circulating Tumor Cells Market, Through 2022 ($ Millions)
    • Table 111: European Circulating Tumor Cells Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 112: Rest of World Circulating Tumor Cells Market, Through 2022 ($ Millions)
    • Table 113: Rest of World Circulating Tumor Cells Market, by Cancer Type, Through 2022 ($ Millions)
    • Table 114: Circulating Tumor Cell Assay Characteristics
    • Table 115: CTC Selected Patents
    • Table 116: Key Patents by Aviva Biosciences
    • Table 117: Commercial Circulating Tumor Cell Technology Platforms

List of Figures

  • Summary Figure: Global Circulating Tumor Cell Technology Market, by Cancer Type, 2012-2022 ($ Millions)
    • Figure 1: Global Cancer Incidence and Mortality, 2012 and 2035 (Millions)
    • Figure 2: Common Types of Cancers in U.S., Estimated New Cases, 2013
    • Figure 3: Colorectal Cancer Incidence Estimates in U.S., 2012-2022
    • Figure 4: Colon and Rectal Cancer Incidence Estimates in U.S., 2013-2022
    • Figure 5: Prostate Cancer Incidence and Mortality Worldwide, 2012 (Thousands)
    • Figure 6: Global Estimated Prostate Cancer Deaths: Age-Standardized Mortality Rates per 100,000 Men, 2012
    • Figure 7: Global Estimated New Cases of Prostate Cancer, 2012-2022
    • Figure 8: New Cases and Deaths of Prostate Cancer in U.S., 2012-2016 (Number)
    • Figure 9: Estimated Prostate Cancer Cases in U.S., 2020 and 2030 (Number)
    • Figure 10: Prostate Cancer Deaths in U.K.: Rate per 100,000 People, 2014
    • Figure 11: Global Cancer Incidence - Estimates, 2008-2030 (Millions)
    • Figure 12: Global Cancer Survivors, 2008 (Millions)
    • Figure 13: Global Cancer Drug Market, 2013-2022 ($ Millions)
    • Figure 14: Global In Vitro Diagnostics Market, 2012-2022 ($ Millions)
    • Figure 15: Global Cancer Biomarkers Market, 2012-2022 ($ Millions)
    • Figure 16: Global Molecular Diagnostics Market, 2012-2022 ($ Millions)
    • Figure 17: Global Circulating Tumor Cell Testing Market, by Region, 2012-2022 ($ Millions)
    • Figure 18: Global Circulating Tumor Cells for Prostate Cancer Market, by Region, 2012-2022 ($ Millions)
    • Figure 19: Global Circulating Tumor Cells for Breast Cancer Market, by Region, 2012-2022 ($ Millions)
    • Figure 20: Global Circulating Tumor Cells for Colorectal Cancer Market, by Region, 2012-2022 ($ Millions)
    • Figure 21: U.S. Circulating Tumor Cells for Prostate Cancer Market, 2012-2022 ($ Millions)
    • Figure 22: U.S. Circulating Tumor Cells Market, by Cancer Type, 2012-2022 ($ Millions)
    • Figure 23: European Circulating Tumor Cells Market, 2012-2022 ($ Millions)
    • Figure 24: European Circulating Tumor Cells Market, by Cancer Type, 2012-2022 ($ Millions)
    • Figure 25: Rest of World Circulating Tumor Cells Market, 2012-2022 ($ Millions)
    • Figure 26: Rest of World Circulating Tumor Cells Market, by Cancer Type, 2012-2022 ($ Millions)
Back to Top